Literature DB >> 33833060

Soluble α-synuclein-antibody complexes activate the NLRP3 inflammasome in hiPSC-derived microglia.

Dorit Trudler1,2,3, Kristopher L Nazor4, Yvonne S Eisele5,6, Titas Grabauskas1,2, Nima Dolatabadi1,2,3, James Parker3, Abdullah Sultan3, Zhenyu Zhong7,8,9, Marshall S Goodwin10,11,12, Yona Levites10,11,12, Todd E Golde10,11,12, Jeffery W Kelly1,2,5, Michael R Sierks13, Nicholas J Schork14,15,16,17, Michael Karin18,8, Rajesh Ambasudhan19,2,3, Stuart A Lipton19,2,3,20,21.   

Abstract

Parkinson's disease is characterized by accumulation of α-synuclein (αSyn). Release of oligomeric/fibrillar αSyn from damaged neurons may potentiate neuronal death in part via microglial activation. Heretofore, it remained unknown if oligomeric/fibrillar αSyn could activate the nucleotide-binding oligomerization domain (NOD)-like receptor (NLR) family pyrin domain-containing 3 (NLRP3) inflammasome in human microglia and whether anti-αSyn antibodies could prevent this effect. Here, we show that αSyn activates the NLRP3 inflammasome in human induced pluripotent stem cell (hiPSC)-derived microglia (hiMG) via dual stimulation involving Toll-like receptor 2 (TLR2) engagement and mitochondrial damage. In vitro, hiMG can be activated by mutant (A53T) αSyn secreted from hiPSC-derived A9-dopaminergic neurons. Surprisingly, αSyn-antibody complexes enhanced rather than suppressed inflammasome-mediated interleukin-1β (IL-1β) secretion, indicating these complexes are neuroinflammatory in a human context. A further increase in inflammation was observed with addition of oligomerized amyloid-β peptide (Aβ) and its cognate antibody. In vivo, engraftment of hiMG with αSyn in humanized mouse brain resulted in caspase-1 activation and neurotoxicity, which was exacerbated by αSyn antibody. These findings may have important implications for antibody therapies aimed at depleting misfolded/aggregated proteins from the human brain, as they may paradoxically trigger inflammation in human microglia.

Entities:  

Keywords:  Alzheimer’s disease; Lewy body dementia; Parkinson’s disease; antibody therapies; neuroinflammation

Year:  2021        PMID: 33833060     DOI: 10.1073/pnas.2025847118

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  21 in total

Review 1.  Inflammasome Activation in Parkinson's Disease.

Authors:  Shannon Jewell; Ashane M Herath; Richard Gordon
Journal:  J Parkinsons Dis       Date:  2022       Impact factor: 5.520

Review 2.  Microglia Phenotypes in Aging and Neurodegenerative Diseases.

Authors:  Menbere Y Wendimu; Shelley B Hooks
Journal:  Cells       Date:  2022-06-30       Impact factor: 7.666

Review 3.  Microglia in Parkinson's Disease.

Authors:  Nadia Stefanova
Journal:  J Parkinsons Dis       Date:  2022       Impact factor: 5.520

Review 4.  Multiple system atrophy.

Authors:  Werner Poewe; Iva Stankovic; Glenda Halliday; Wassilios G Meissner; Gregor K Wenning; Maria Teresa Pellecchia; Klaus Seppi; Jose-Alberto Palma; Horacio Kaufmann
Journal:  Nat Rev Dis Primers       Date:  2022-08-25       Impact factor: 65.038

5.  CD36-Binding Amphiphilic Nanoparticles for Attenuation of Alpha Synuclein-Induced Microglial Activation.

Authors:  Nanxia Zhao; Nicola L Francis; Shuang Song; Vladyslav Kholodovych; Hannah R Calvelli; Cody L Hoop; Zhiping P Pang; Jean Baum; Kathryn E Uhrich; Prabhas V Moghe
Journal:  Adv Nanobiomed Res       Date:  2022-03-22

6.  Remifentanil inhibits the inflammatory response of BV2 microglia and protects PC12 cells from damage caused by microglia activation.

Authors:  Yankui Huang; Qingxiang Cai; Huihui Liu; Yong Wang; Wuhua Ma
Journal:  Bioengineered       Date:  2022-05       Impact factor: 6.832

7.  The circadian clock protein Rev-erbα provides neuroprotection and attenuates neuroinflammation against Parkinson's disease via the microglial NLRP3 inflammasome.

Authors:  Liang Kou; Xiaosa Chi; Yadi Sun; Chao Han; Fang Wan; Junjie Hu; Sijia Yin; Jiawei Wu; Yunna Li; Qiulu Zhou; Wenkai Zou; Nian Xiong; Jinsha Huang; Yun Xia; Tao Wang
Journal:  J Neuroinflammation       Date:  2022-06-06       Impact factor: 9.587

Review 8.  The NLRP3 Inflammasome Pathway: A Review of Mechanisms and Inhibitors for the Treatment of Inflammatory Diseases.

Authors:  Hallie M Blevins; Yiming Xu; Savannah Biby; Shijun Zhang
Journal:  Front Aging Neurosci       Date:  2022-06-10       Impact factor: 5.702

Review 9.  Multi-Target Effects of ß-Caryophyllene and Carnosic Acid at the Crossroads of Mitochondrial Dysfunction and Neurodegeneration: From Oxidative Stress to Microglia-Mediated Neuroinflammation.

Authors:  Roberto Iorio; Giuseppe Celenza; Sabrina Petricca
Journal:  Antioxidants (Basel)       Date:  2022-06-18

Review 10.  The Contribution of Microglia to Neuroinflammation in Parkinson's Disease.

Authors:  Katja Badanjak; Sonja Fixemer; Semra Smajić; Alexander Skupin; Anne Grünewald
Journal:  Int J Mol Sci       Date:  2021-04-28       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.